Anti-Human CD194 (CCR4) (Mogamulizumab) - Fc Muted™
Antibody Isotype:
Human IgG1κ
Antibody Clonality:
Monoclonal
Applications:- Depletion
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Functional Study
Shipping:
2 - 8°C Wet Ice
Storage:
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C.?Avoid Repeated Freeze Thaw Cycles.
No additional charges, what you see is what you pay! *
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available!
Contact us to find what you can save.
This product comes from:
US.
Typical lead time:
14-21 working days.
Contact us for more accurate information.
- Further Information
- References
- Show All
Further Information
CCR4 is expressed on a variety of cell types: T lymphocytes (Th2, Th17, and regulatory T cells), platelets, NK cells, monocytes, macrophages, dendritic cells, neurons, microglia, and astroglia.1 Expression of CCR4 is increased on leukemic cells in cutaneous T-cell lymphoma (CTCL).2
? 5.0 mg/ml
Purified No Carrier Protein
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Human CD194
Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.3 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1?infected cells and the levels of inflammatory markers related to HTLV-1?Associated Myelopathy.5
1233
?95% monomer by analytical SEC
CD194